CTOs on the Move


 
Our platforms use silicon nanopore chips and proprietary biochemistry to accurately detect and differentiate single molecules. We will help transform point-of-care testing and third generation sequencing.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.ontera.bio
  • 2155 Delaware Avenue Suite 225
    Santa Cruz, CA USA 95060

Executives

Name Title Contact Details
Raparti Swayambhu
Vice President of Information Software Profile

Similar Companies

Nura Inc

Nura Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ImClone Systems

ImClone Systems is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.

Janssen Research and Development

Janssen Research and Development is a Horsham, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genelux

Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company`s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination with platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux` discovery and development efforts revolves around the company`s proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.

Corventis

Corventis is a San Jose, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.